What's Happening?
Amylyx Pharmaceuticals has reported the completion of enrollment for its pivotal Phase 3 LUCIDITY clinical trial of avexitide, a glucagon-like peptide-1 (GLP-1) receptor antagonist, aimed at treating post-bariatric
hypoglycemia (PBH). The trial, which enrolled 78 participants, is a multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of avexitide in adults who have undergone Roux-en-Y gastric bypass surgery. The company anticipates a topline data readout in the third quarter of 2026. Avexitide has received Breakthrough Therapy Designation from the FDA for PBH, a condition characterized by excessive insulin secretion leading to recurrent hypoglycemic events. Amylyx is also advancing its LUMINA trial for AMX0114, targeting amyotrophic lateral sclerosis (ALS), and has initiated an Expanded Access Program for avexitide.
Why It's Important?
The development of avexitide is significant as it addresses a critical unmet need for patients suffering from post-bariatric hypoglycemia, a condition affecting approximately 8% of individuals who undergo bariatric surgery in the U.S. Currently, there are no FDA-approved therapies for PBH, which can lead to severe hypoglycemic events and impact quality of life. The successful completion of the LUCIDITY trial could lead to the first approved treatment for this condition, potentially improving patient outcomes and reducing healthcare burdens associated with managing PBH. Additionally, Amylyx's progress in ALS research with AMX0114 highlights the company's commitment to addressing rare and debilitating diseases.
What's Next?
Amylyx plans to release the topline data from the LUCIDITY trial in Q3 2026, which will be crucial for determining the next steps in the regulatory approval process for avexitide. If the results are positive, the company aims to commercialize avexitide by 2027. The ongoing Expanded Access Program will provide early access to avexitide for eligible patients, potentially offering relief to those currently without effective treatment options. Furthermore, Amylyx is preparing for the presentation of early biomarker data from its LUMINA trial at the ENCALS Annual Meeting, which could provide insights into the treatment of ALS.
